Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An open-label, multicenter phase Ib/II study of 9MW2821 alone or in combination with other antitumor agents in patients with advanced solid tumors
CTR20251328Phase 2Active
- Sponsor
- Mabwell
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bulumtatug fuvedotin in Nonhematologic neoplasms (2 arms), sponsored by Mabwell. Primary endpoints: Safety (phase Ib): adverse events and serious adverse events and Objective response rate (phase II, investigator-assessed per RECIST v1.1). Started Jun 2025; status: active.
02
Drugs
bulumtatug fuvedotin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251328.